Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 33.3 | uM | 7830.068 | 0.7331 | 0.6889 | 1.8365 | |
| HCC1806 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 167 | uM | 7830.068 | 0.8159 | 0.7902 | 1.8365 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7834.068 | 0.9239 | 0.9240 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7834.068 | 0.9454 | 0.9458 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7834.068 | 0.7903 | 0.7823 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7834.068 | 0.6676 | 0.6410 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7834.068 | 0.6372 | 0.6039 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 1.33 | uM | 7834.068 | 0.6351 | 0.6013 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 6.67 | uM | 7834.068 | 0.6434 | 0.6115 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 33.3 | uM | 7834.068 | 0.4480 | 0.3497 | 2.0420 | |
| HCC1937 | TNBC | Basal A | Sirolimus | MTOR | MTOR | 167 | uM | 7834.068 | 0.0487 | -0.5448 | 2.0420 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7457.068 | 0.8047 | 0.7720 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7457.068 | 0.6574 | 0.5832 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7457.068 | 0.5958 | 0.4988 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7457.068 | 0.4769 | 0.3240 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7457.068 | 0.4996 | 0.3588 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 1.33 | uM | 7457.068 | 0.4670 | 0.3086 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 6.67 | uM | 7457.068 | 0.4998 | 0.3591 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 33.3 | uM | 7457.068 | 0.3063 | 0.0346 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 167 | uM | 7457.068 | 0.4386 | 0.2637 | 1.7951 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7836.068 | 0.8089 | 0.7562 | 1.6317 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7836.068 | 0.6756 | 0.5728 | 1.6317 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7836.068 | 0.5481 | 0.3835 | 1.6317 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7836.068 | 0.4811 | 0.2772 | 1.6317 | |
| HCC1954 | HER2amp | Basal A | Sirolimus | MTOR | MTOR | 0.267 | uM | 7836.068 | 0.5197 | 0.3391 | 1.6317 |